Cargando…

Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study

The aims of this multicentric retrospective study were to assess in a real-world setting the effectiveness and safety of canagliflozin 100 mg/d (CANA100) as an add-on to the background antihyperglycemic therapy, and to evaluate the intensification of prior sodium–glucose co-transporter type 2 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorgojo-Martínez, Juan J., Gargallo-Fernández, Manuel A., Galdón Sanz-Pastor, Alba, Antón-Bravo, Teresa, Brito-Sanfiel, Miguel, Wong-Cruz, Jaime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408903/
https://www.ncbi.nlm.nih.gov/pubmed/32708943
http://dx.doi.org/10.3390/jcm9072275
_version_ 1783567940035018752
author Gorgojo-Martínez, Juan J.
Gargallo-Fernández, Manuel A.
Galdón Sanz-Pastor, Alba
Antón-Bravo, Teresa
Brito-Sanfiel, Miguel
Wong-Cruz, Jaime
author_facet Gorgojo-Martínez, Juan J.
Gargallo-Fernández, Manuel A.
Galdón Sanz-Pastor, Alba
Antón-Bravo, Teresa
Brito-Sanfiel, Miguel
Wong-Cruz, Jaime
author_sort Gorgojo-Martínez, Juan J.
collection PubMed
description The aims of this multicentric retrospective study were to assess in a real-world setting the effectiveness and safety of canagliflozin 100 mg/d (CANA100) as an add-on to the background antihyperglycemic therapy, and to evaluate the intensification of prior sodium–glucose co-transporter type 2 inhibitor (SGLT-2i) therapy by switching to canagliflozin 300 mg/d (CANA300) in patients with T2DM. One cohort of SGLT2i-naïve patients with T2DM who were initiated on CANA100 and a second cohort of patients with prior background SGLT-2i therapy who switched to CANA300 were included in the study. The primary outcome of the study was the mean change in HbA1c over the follow-up time. In total, 583 patients were included—279 in the cohort of CANA100 (HbA1c 8.05%, weight 94.9 kg) and 304 in the cohort of CANA300 (HbA1c 7.51%, weight 92.0 kg). Median follow-up periods in both cohorts were 9.1 and 15.4 months respectively. CANA100 was associated to significant reductions in HbA1c (−0.90%) and weight (−4.1 kg) at the end of the follow-up. In those patients with baseline HbA1c > 8% (mean 9.25%), CANA100 lowered HbA1c levels by 1.51%. In the second cohort, patients switching to CANA300 experienced a significant decrease in HbA1c (−0.35%) and weight (−2.1 kg). In those patients with baseline HbA1c > 8% (mean 8.94%), CANA300 lowered HbA1c levels by 1.12%. There were significant improvements in blood pressure in both cohorts. No unexpected adverse events were reported. In summary, CANA100 (as an add-on therapy) and CANA300 (switching from prior SGLT-2i therapy) significantly improved several cardiometabolic parameters in patients with T2DM.
format Online
Article
Text
id pubmed-7408903
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74089032020-08-13 Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study Gorgojo-Martínez, Juan J. Gargallo-Fernández, Manuel A. Galdón Sanz-Pastor, Alba Antón-Bravo, Teresa Brito-Sanfiel, Miguel Wong-Cruz, Jaime J Clin Med Article The aims of this multicentric retrospective study were to assess in a real-world setting the effectiveness and safety of canagliflozin 100 mg/d (CANA100) as an add-on to the background antihyperglycemic therapy, and to evaluate the intensification of prior sodium–glucose co-transporter type 2 inhibitor (SGLT-2i) therapy by switching to canagliflozin 300 mg/d (CANA300) in patients with T2DM. One cohort of SGLT2i-naïve patients with T2DM who were initiated on CANA100 and a second cohort of patients with prior background SGLT-2i therapy who switched to CANA300 were included in the study. The primary outcome of the study was the mean change in HbA1c over the follow-up time. In total, 583 patients were included—279 in the cohort of CANA100 (HbA1c 8.05%, weight 94.9 kg) and 304 in the cohort of CANA300 (HbA1c 7.51%, weight 92.0 kg). Median follow-up periods in both cohorts were 9.1 and 15.4 months respectively. CANA100 was associated to significant reductions in HbA1c (−0.90%) and weight (−4.1 kg) at the end of the follow-up. In those patients with baseline HbA1c > 8% (mean 9.25%), CANA100 lowered HbA1c levels by 1.51%. In the second cohort, patients switching to CANA300 experienced a significant decrease in HbA1c (−0.35%) and weight (−2.1 kg). In those patients with baseline HbA1c > 8% (mean 8.94%), CANA300 lowered HbA1c levels by 1.12%. There were significant improvements in blood pressure in both cohorts. No unexpected adverse events were reported. In summary, CANA100 (as an add-on therapy) and CANA300 (switching from prior SGLT-2i therapy) significantly improved several cardiometabolic parameters in patients with T2DM. MDPI 2020-07-17 /pmc/articles/PMC7408903/ /pubmed/32708943 http://dx.doi.org/10.3390/jcm9072275 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gorgojo-Martínez, Juan J.
Gargallo-Fernández, Manuel A.
Galdón Sanz-Pastor, Alba
Antón-Bravo, Teresa
Brito-Sanfiel, Miguel
Wong-Cruz, Jaime
Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
title Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
title_full Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
title_fullStr Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
title_full_unstemmed Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
title_short Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
title_sort real-world clinical outcomes associated with canagliflozin in patients with type 2 diabetes mellitus in spain: the real-wecan study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408903/
https://www.ncbi.nlm.nih.gov/pubmed/32708943
http://dx.doi.org/10.3390/jcm9072275
work_keys_str_mv AT gorgojomartinezjuanj realworldclinicaloutcomesassociatedwithcanagliflozininpatientswithtype2diabetesmellitusinspaintherealwecanstudy
AT gargallofernandezmanuela realworldclinicaloutcomesassociatedwithcanagliflozininpatientswithtype2diabetesmellitusinspaintherealwecanstudy
AT galdonsanzpastoralba realworldclinicaloutcomesassociatedwithcanagliflozininpatientswithtype2diabetesmellitusinspaintherealwecanstudy
AT antonbravoteresa realworldclinicaloutcomesassociatedwithcanagliflozininpatientswithtype2diabetesmellitusinspaintherealwecanstudy
AT britosanfielmiguel realworldclinicaloutcomesassociatedwithcanagliflozininpatientswithtype2diabetesmellitusinspaintherealwecanstudy
AT wongcruzjaime realworldclinicaloutcomesassociatedwithcanagliflozininpatientswithtype2diabetesmellitusinspaintherealwecanstudy